NGM Bio Announces Initiation of Phase 1/1b Clinical Trial of NGM831 for the Treatment of Patients with Advanced Solid Tumors Portfolio News / Karina Tin March 31, 2022 NGM Bio Announces Initiation of Phase 1/1b Clinical Trial of NGM831 for the Treatment of Patients with Advanced Solid Tumors Read More »
Ribon Therapeutics Announces Initiation of Phase 1b/2 Study of RBN-2397 in Combination with Pembrolizumab in Patients with Squamous Cell Carcinoma of the Lung Portfolio News / Karina Tin March 29, 2022 Ribon Therapeutics Announces Initiation of Phase 1b/2 Study of RBN-2397 in Combination with Pembrolizumab in Patients with Squamous Cell Carcinoma of the Lung Read More »
Nurix Therapeutics Awarded Innovation Passport for Entry into Innovative Licensing and Access Pathway (ILAP) in the United Kingdom for NX-1607 Portfolio News / Karina Tin March 29, 2022 Nurix Therapeutics Awarded Innovation Passport for Entry into Innovative Licensing and Access Pathway (ILAP) in the United Kingdom for NX-1607 Read More »
RAPT Therapeutics Announces Biomarker Data from Phase 1B Trial of RPT193 Consistent with Disease Modification in Atopic Dermatitis Portfolio News / Karina Tin March 28, 2022 RAPT Therapeutics Announces Biomarker Data from Phase 1B Trial of RPT193 Consistent with Disease Modification in Atopic Dermatitis Read More »
Surrozen Reports Fourth Quarter and Full Year 2021 Financial Results Portfolio News / Karina Tin March 24, 2022 Surrozen Reports Fourth Quarter and Full Year 2021 Financial Results Read More »
Eikon Therapeutics Announces the Appointment of Dr. Roy D. Baynes as Executive Vice President and Chief Medical Officer Portfolio News / Karina Tin March 23, 2022 Eikon Therapeutics Announces the Appointment of Dr. Roy D. Baynes as Executive Vice President and Chief Medical Officer Read More »
Ribon Therapeutics Initiates First-in-Human Phase 1 Clinical Study of RBN-3143 for the Treatment of Atopic Dermatitis Portfolio News / Karina Tin March 22, 2022 Ribon Therapeutics Initiates First-in-Human Phase 1 Clinical Study of RBN-3143 for the Treatment of Atopic Dermatitis Read More »
NGM Bio to Host the First of Four Virtual R&D Events on March 30, 2022 Portfolio News / Karina Tin March 21, 2022 NGM Bio to Host the First of Four Virtual R&D Events on March 30, 2022 Read More »
ORIC Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Operational Update Portfolio News / Karina Tin March 21, 2022 ORIC Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Operational Update Read More »
eFFECTOR Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update Portfolio News / Karina Tin March 16, 2022 eFFECTOR Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update Read More »